Canopy Growth (CGC) Cash & Equivalents (2017 - 2026)
Canopy Growth (CGC) reported Cash & Equivalents of $265.9 million for Q1 2026, up 235.27% on a YoY basis from $79.3 million in Q1 2025, and little changed sequentially from $266.3 million in Q4 2025.
Canopy Growth (CGC) Cash & Equivalents (2017 - 2026) Analysis & Trends
Canopy Growth (CGC) has 10 years of Cash & Equivalents data on file, last reported at $265.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents rose 235.27% year-over-year to $265.9 million; the trailing twelve-month figure through Mar 2026 stood at $265.9 million (up 235.27% YoY), and the FY2026 full-year result was $265.9 million, up 235.27% from the prior year.
- Cash & Equivalents steadied at $265.9 million in Q1 2026, from $266.3 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $612.6 million in Q1 2022 to a low of $79.3 million in Q1 2025.
- A 5-year average of $270.3 million and a median of $181.2 million in 2023 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents tumbled 76.21% in 2023 and soared 235.27% in 2026, its largest moves.
- Tracing CGC's Cash & Equivalents over 5 years: stood at $440.6 million in 2022, then plunged by 76.21% to $104.9 million in 2023, then advanced by 10.54% to $115.9 million in 2024, then jumped by 129.74% to $266.3 million in 2025, then dropped by 0.13% to $265.9 million in 2026.
- Business Quant data shows CGC's Cash & Equivalents at $265.9 million in Q1 2026, $266.3 million in Q4 2025, and $94.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.58 Bn | 86.72 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.33 Bn | 30.39 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | 1.28 Bn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | 3.97 Mn |
| 7 | Viatris | 20.29 Bn | 18.49 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.93 Bn | 16.62 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Canopy Growth | 270.50 Mn | 4.57 Mn | - | 265.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 265.93 Mn |
| Dec 31, 2025 | 266.27 Mn |
| Sep 30, 2025 | 94.07 Mn |
| Jun 30, 2025 | 91.08 Mn |
| Mar 31, 2025 | 79.32 Mn |
| Dec 31, 2024 | 115.90 Mn |
| Sep 30, 2024 | 167.44 Mn |
| Jun 30, 2024 | 140.49 Mn |
| Mar 31, 2024 | 126.38 Mn |
| Dec 31, 2023 | 104.85 Mn |
| Sep 30, 2023 | 181.24 Mn |
| Jun 30, 2023 | 396.99 Mn |
| Mar 31, 2023 | 335.19 Mn |
| Dec 31, 2022 | 440.64 Mn |
| Sep 30, 2022 | 572.54 Mn |
| Jun 30, 2022 | 603.55 Mn |
| Mar 31, 2022 | 612.64 Mn |
| Dec 31, 2021 | 488.02 Mn |
| Sep 30, 2021 | 641.58 Mn |
| Jun 30, 2021 | 455.45 Mn |